Monoclonal antibody therapy of human gliomas: current status and future approaches.

Published

Journal Article (Review)

The development of immunotherapeutic protocols for the treatment of human CNS neoplasia over the past two decades has been impressive. Several crucial aspects have been defined, characterized, and in many cases, optimized (Wikstrand CJ, Zalutsky MR, Bigner DD: In: Liau LM, Bigner DD (eds) Brain Tumor Immunotherapy. Humana Press (in press), 2000). Specific Mabs or constructs reacting with targetable antigens are currently available and in clinical trial. In addition, additional antigens currently under study (angiogenesis-related markers, developmentally associated antigens for medulloblastoma such as L1, and the identification of new targets by SAGE, just in its infancy, will provide a veritable library of available targets for therapy. The molecular engineering and affinity maturation techniques being applied to Mab fragment optimization have already been rapidly effective in generating a variety of Mab constructs of appropriate affinity for clinical trial; as new targets are defined, and experience is accrued with the various constructs currently and prospectively available, the optimal targeting of a multitude of antigens will be possible.

Full Text

Duke Authors

Cited Authors

  • Wikstrand, CJ; Cokgor, I; Sampson, JH; Bigner, DD

Published Date

  • 1999

Published In

Volume / Issue

  • 18 / 4

Start / End Page

  • 451 - 464

PubMed ID

  • 10855788

Pubmed Central ID

  • 10855788

International Standard Serial Number (ISSN)

  • 0167-7659

Digital Object Identifier (DOI)

  • 10.1023/a:1006354102377

Language

  • eng

Conference Location

  • Netherlands